Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pharmas Pursue Tech Deals To Speed Drug Development, Measure Outcomes

Executive Summary

Deals for technology platforms allow more of a multiple-shots-on-goal approach as opposed to taking a risk with one or two candidates.

You may also be interested in...



Start-Up Quarterly Statistics, Q4 2016

A review of biopharma start-up dealmaking and financing from October through December 2016, based on data from Strategic Transactions.

Novartis’s Evolving R&D: An Interview With CMO Narasimhan At J.P. Morgan

Novartis is under pressure to deliver new drugs in areas like oncology, cardiovascular disease and dermatology, where it is making significant investments. Chief Medical Officer Vasant Narasimhan talked about the company’s strategy in these areas and others, the company’s recent R&D reorganization and business development in an interview during the J.P. Morgan Healthcare Conference.

AstraZeneca Puts Bicycles To Work In Multitarget Deal

AstraZeneca has entered a broad early stage collaboration with Bicycle Therapeutics to discover and develop bicyclic peptides (Bicycles). If all aspects of the multitarget deal reach fruition, the deal could be worth up to £1bn for the small biotech company.

Related Content

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

SC098092

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel